Susan P. Carpenter

1.0k total citations
20 papers, 839 citations indexed

About

Susan P. Carpenter is a scholar working on Radiology, Nuclear Medicine and Imaging, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, Susan P. Carpenter has authored 20 papers receiving a total of 839 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Radiology, Nuclear Medicine and Imaging, 7 papers in Genetics and 7 papers in Pathology and Forensic Medicine. Recurrent topics in Susan P. Carpenter's work include Monoclonal and Polyclonal Antibodies Research (8 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Pharmacogenetics and Drug Metabolism (5 papers). Susan P. Carpenter is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (8 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Pharmacogenetics and Drug Metabolism (5 papers). Susan P. Carpenter collaborates with scholars based in United States, United Kingdom and Canada. Susan P. Carpenter's co-authors include Judy L. Raucy, Amanda M. VanDenburgh, Jerome M. Lasker, Joseph Shan, William R. Shapiro, Kuankuan Chen, Richard F. Brubaker, Cherie B. Nau, Sunil J. Patel and Anthony L. Asher and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

In The Last Decade

Susan P. Carpenter

19 papers receiving 809 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Susan P. Carpenter United States 14 195 193 160 157 157 20 839
Basharut A. Syed United Kingdom 15 46 0.2× 77 0.4× 94 0.6× 250 1.6× 77 0.5× 24 678
Ming Tan United States 16 15 0.1× 83 0.4× 75 0.5× 401 2.6× 289 1.8× 38 957
Luv Patel United States 12 204 1.0× 170 0.9× 65 0.4× 459 2.9× 221 1.4× 33 877
Walter Voigt United States 13 24 0.1× 39 0.2× 27 0.2× 160 1.0× 174 1.1× 34 825
Agata Filip Poland 17 29 0.1× 22 0.1× 107 0.7× 319 2.0× 160 1.0× 67 751
Erika Rimondi Italy 20 32 0.2× 50 0.3× 96 0.6× 830 5.3× 356 2.3× 65 1.3k
Susan Walther United States 11 24 0.1× 12 0.1× 66 0.4× 245 1.6× 272 1.7× 17 693
Lori Capone Switzerland 9 20 0.1× 25 0.1× 73 0.5× 466 3.0× 179 1.1× 13 1.0k
Vinod S. Ramgolam United States 11 55 0.3× 45 0.2× 10 0.1× 234 1.5× 181 1.2× 16 825
Lisa Iacono United States 14 10 0.1× 52 0.3× 211 1.3× 320 2.0× 278 1.8× 34 761

Countries citing papers authored by Susan P. Carpenter

Since Specialization
Citations

This map shows the geographic impact of Susan P. Carpenter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan P. Carpenter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan P. Carpenter more than expected).

Fields of papers citing papers by Susan P. Carpenter

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susan P. Carpenter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan P. Carpenter. The network helps show where Susan P. Carpenter may publish in the future.

Co-authorship network of co-authors of Susan P. Carpenter

This figure shows the co-authorship network connecting the top 25 collaborators of Susan P. Carpenter. A scholar is included among the top collaborators of Susan P. Carpenter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susan P. Carpenter. Susan P. Carpenter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Raje, Noopur, Edward A. Faber, Paul G. Richardson, et al.. (2016). Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma. Clinical Cancer Research. 22(23). 5688–5695. 22 indexed citations
2.
Rathinam, Vijay, Aisling Dunne, Thaddeus Carlson, et al.. (2014). TRIL Is Involved in Cytokine Production in the Brain following Escherichia coli Infection. The Journal of Immunology. 193(4). 1911–1919. 16 indexed citations
3.
Ganjoo, Kristen N., Sven de Vos, Brad Pohlman, et al.. (2014). Phase 1/2 Study of Ocaratuzumab, an Fc-Engineered Humanized Anti-CD20 Monoclonal Antibody, in Low-Affinity FcγRIIIa Patients with Previously Treated Follicular Lymphoma. Leukemia & lymphoma. 56(1). 42–48. 28 indexed citations
4.
Forero‐Torres, Andres, Sven de Vos, Brad Pohlman, et al.. (2012). Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in FcγRIIIa-Genotyped Patients with Previously Treated Follicular Lymphoma. Clinical Cancer Research. 18(5). 1395–1403. 54 indexed citations
5.
Raje, Noopur, Edward A. Faber, Paul G. Richardson, et al.. (2012). Phase 1 Study of Tabalumab, a Human Anti-BAFF Antibody and Bortezomib in Patients with Previously-Treated Multiple Myeloma. Blood. 120(21). 447–447. 10 indexed citations
6.
Ganjoo, Kristen N., Andres Forero, Brad Pohlman, et al.. (2011). Sustained Depletion of B-Cells by a Humanized, Fc-Engineered Anti-CD20 Antibody, AME-133v, in Patients with Relapsed Follicular Lymphoma. Blood. 118(21). 4977–4977. 1 indexed citations
7.
8.
Hohl, Raymond J., Edward A. Faber, PG Richardson, et al.. (2011). Phase I study of LY2127399, a human anti-BAFF antibody, and bortezomib in patients with previously treated multiple myeloma.. Journal of Clinical Oncology. 29(15_suppl). 8012–8012. 12 indexed citations
9.
10.
Shapiro, William R., Susan P. Carpenter, Karen Roberts, & Joseph Shan. (2006). 131I-chTNT-1/B mAb: tumour necrosis therapy for malignant astrocytic glioma. Expert Opinion on Biological Therapy. 6(5). 539–545. 36 indexed citations
11.
Patel, Sunil J., William R. Shapiro, Douglas W. Laske, et al.. (2005). Safety and Feasibility of Convection-enhanced Delivery of Cotara for the Treatment of Malignant Glioma: Initial Experience in 51 Patients. Neurosurgery. 56(6). 1243–1253. 136 indexed citations
12.
Walters, Thomas R., Harvey Dubiner, Susan P. Carpenter, Bashir Ahmad Khan, & Amanda M. VanDenburgh. (2004). 24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial. Survey of Ophthalmology. 49(2). S26–S35. 82 indexed citations
13.
Brubaker, Richard F., et al.. (2001). Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics. American Journal of Ophthalmology. 131(1). 19–24. 124 indexed citations
14.
Raucy, Judy L., M.C. Kearins, Sanjeev Arora, et al.. (1999). CYP2E1 Expression in Human Lymphocytes From Various Ethnic Populations. Alcoholism Clinical and Experimental Research. 23(12). 1868–1874. 26 indexed citations
15.
Raucy, Judy L., M.C. Kearins, Sanjeev Arora, et al.. (1999). CYP2E1 Expression in Human Lymphocytes From Various Ethnic Populations. Alcoholism Clinical and Experimental Research. 23(12). 1868–1868.
16.
Carpenter, Susan P., et al.. (1997). Ethanol-Mediated Transplacental Induction of CYP2E1 in Fetal Rat Liver. Journal of Pharmacology and Experimental Therapeutics. 282(2). 1028–1036. 18 indexed citations
17.
Eckmann, Lars, Michael B. Dwinell, Susan P. Carpenter, et al.. (1997). Human hepatocytes express an array of proinflammatory cytokines after agonist stimulation or bacterial invasion. American Journal of Physiology-Gastrointestinal and Liver Physiology. 273(2). G322–G332. 87 indexed citations
18.
Raucy, Judy L., et al.. (1997). Human lymphocyte cytochrome P450 2E1, a putative marker for alcohol-mediated changes in hepatic chlorzoxazone activity.. PubMed. 25(12). 1429–35. 78 indexed citations
19.
Carpenter, Susan P., Jerome M. Lasker, & Judy L. Raucy. (1996). Expression, induction, and catalytic activity of the ethanol-inducible cytochrome P450 (CYP2E1) in human fetal liver and hepatocytes.. Molecular Pharmacology. 49(2). 260–268. 82 indexed citations
20.
Raucy, Judy L., G. Paul Curley, & Susan P. Carpenter. (1995). Use of Lymphocytes for Assessing Ethanol‐Mediated Alterations in the Expression of Hepatic Cytochrome P4502E1. Alcoholism Clinical and Experimental Research. 19(6). 1369–1375. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Basharut A. Syed Breakdown of academic impact, for papers by Ming Tan Breakdown of academic impact, for papers by Luv Patel Breakdown of academic impact, for papers by Walter Voigt Breakdown of academic impact, for papers by Agata Filip Breakdown of academic impact, for papers by Erika Rimondi Breakdown of academic impact, for papers by Susan Walther Breakdown of academic impact, for papers by Lori Capone Breakdown of academic impact, for papers by Vinod S. Ramgolam Breakdown of academic impact, for papers by Lisa Iacono
Rankless by CCL
2026